Aspen Pharmacare Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA), is conducting a retail level recall of Zantac (ranitidine) tablets, effervescent tablets, syrup and ampoules.
The TGA has not requested that a Dear Doctor letter be sent for this retail level product recall.
We are informing you as the potentially affected product may have been supplied to your clinic or hospital, or you may have prescribed or recommended Zantac to your patients.
A retail level recall means that all retail outlets stocking Zantac will return their stock and be given a refund. Outlets include retail and hospital pharmacies, grocery stores and wholesalers.
Please read the full communication below:
Content Last Reviewed On October 3, 2019